Drugs in R & D

, Volume 1, Issue 2, pp 187–188 | Cite as


UK 109496
Section 2: Antifungal Agent Adis R&D Profile


Fluconazole Triazole Itraconazole Candidiasis Voriconazole 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mellsop H. New antifungal agents needed for immuno-compromised patients. Inpharma 1995 Dec 2; 1015: 9–10CrossRefGoogle Scholar
  2. 2.
    Jack D. Voriconazole: a natural successor to fluconazole? Inpharma 1998 Jul 18; 1146: 7–8CrossRefGoogle Scholar
  3. 3.
    New antifungals highlighted at ICAAC. Marketletter 1997 Nov 17; 24: 26–7Google Scholar
  4. 4.
    Martin MV, Yeats J, Hitchcock CA. Voriconazole (UK-109,496): a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental Aspergillus endocarditis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, 114Google Scholar
  5. 5.
    Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998 Aug; 17: 573–5PubMedGoogle Scholar
  6. 6.
    Cuenca-Estrella M, Rodríguez-Tudela JL, Mellado E, et al. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998 Oct; 42: 531–3PubMedCrossRefGoogle Scholar
  7. 7.
    Wildfeuer A, Seidl HP, Paule I, et al. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin. Arzneimittel Forschung 1997 Nov; 47: 1257–63PubMedGoogle Scholar
  8. 8.
    Kauffman CA, Zarins LT. In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis 1998 May; 31: 297–300PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations